Literature DB >> 16769983

Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors.

Eric K Rowinsky.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16769983     DOI： 10.1200/JCO.2006.05.9808

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  16 in total

Review 1.  Inhibition of Ras for cancer treatment: the search continues.

Authors:  Antonio T Baines; Dapeng Xu; Channing J Der
Journal:  Future Med Chem       Date:  2011-10       Impact factor: 3.808

2.  Drug discovery: Pocket of opportunity.

Authors:  Gideon Bollag; Chao Zhang
Journal:  Nature       Date:  2013-11-20       Impact factor: 49.962

3.  An oxanthroquinone derivative that disrupts RAS plasma membrane localization inhibits cancer cell growth.

Authors:  Lingxiao Tan; Kwang-Jin Cho; Pratik Neupane; Robert J Capon; John F Hancock
Journal:  J Biol Chem       Date:  2018-07-03       Impact factor: 5.157

4.  Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice.

Authors:  Maria E Balasis; Kara D Forinash; Y Ann Chen; William J Fulp; Domenico Coppola; Andrew D Hamilton; Jin Q Cheng; Saïd M Sebti
Journal:  Clin Cancer Res       Date:  2011-05-01       Impact factor: 12.531

5.  Acylpeptide hydrolase is a novel regulator of KRAS plasma membrane localization and function.

Authors:  Lingxiao Tan; Kwang-Jin Cho; Walaa E Kattan; Christian M Garrido; Yong Zhou; Pratik Neupane; Robert J Capon; John F Hancock
Journal:  J Cell Sci       Date:  2019-07-31       Impact factor: 5.285

6.  Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma.

Authors:  Daphne A Haas-Kogan; Anuradha Banerjee; Mehmet Kocak; Michael D Prados; J Russell Geyer; Maryam Fouladi; Tracy McKnight; Tina Young Poussaint; Alberto Broniscer; Susan M Blaney; James M Boyett; Larry E Kun
Journal:  Neuro Oncol       Date:  2008-04-16       Impact factor: 12.300

7.  Caged protein prenyltransferase substrates: tools for understanding protein prenylation.

Authors:  Amanda J DeGraw; Michael A Hast; Juhua Xu; Daniel Mullen; Lorena S Beese; George Barany; Mark D Distefano
Journal:  Chem Biol Drug Des       Date:  2008-09       Impact factor: 2.817

8.  Fendiline inhibits K-Ras plasma membrane localization and blocks K-Ras signal transmission.

Authors:  Dharini van der Hoeven; Kwang-jin Cho; Xiaoping Ma; Sravanthi Chigurupati; Robert G Parton; John F Hancock
Journal:  Mol Cell Biol       Date:  2012-11-05       Impact factor: 4.272

Review 9.  A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer.

Authors:  Neil Vasan; Julie L Boyer; Roy S Herbst
Journal:  Clin Cancer Res       Date:  2014-06-03       Impact factor: 12.531

10.  Sphingomyelin Metabolism Is a Regulator of K-Ras Function.

Authors:  Dharini van der Hoeven; Kwang-Jin Cho; Yong Zhou; Xiaoping Ma; Wei Chen; Ali Naji; Dina Montufar-Solis; Yan Zuo; Sarah E Kovar; Kandice R Levental; Jeffrey A Frost; Ransome van der Hoeven; John F Hancock
Journal:  Mol Cell Biol       Date:  2018-01-16       Impact factor: 4.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.